A few studies have systematically analyzed the outcomes of therapeutic approaches for NPM-ALK+ ALCL, and, not unexpectedly, most of these studies focused on pediatric patients [6-13]. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.